Crinetics Pharmaceuticals, Inc.
CRNX
Rankning i aktier
#2228
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Aktiekurs
$84.95
Senast synkroniserad: 2026-09-01
Marknadsvärde
$9.00B
Förändring (1 dag)
0.00%
Förändring (1 år)
98.25%
Land
US
Handel Crinetics Pharmaceuticals, Inc. (CRNX)
Kategori
Healthcare
Vinst för Crinetics Pharmaceuticals, Inc. (CRNX)
Vinst i Jun 2026 TTM: $-501.43M
Enligt de senaste finansiella rapporterna från Crinetics Pharmaceuticals, Inc. är företagets nuvarande vinst $-501.43M. År 2023 hade företaget en vinst på $-214.53M, en minskning jämfört med vinsten år 2022 som var $-163.92M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Crinetics Pharmaceuticals, Inc. från 2016 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $-501.43M | 68.03% |
| 2024 | $-298.41M | 39.10% |
| 2023 | $-214.53M | 30.88% |
| 2022 | $-163.92M | 52.28% |
| 2021 | $-107.64M | 45.83% |
| 2020 | $-73.81M | 46.39% |
| 2019 | $-50.42M | 85.96% |
| 2018 | $-27.12M | 196.11% |
| 2017 | $-9.16M | 52.13% |
| 2016 | $-6.02M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $5.27B | -1,151.98% |
US
|
|
| $-3.09B | 515.64% |
US
|
|
| $-4.02B | 700.95% |
AU
|
|
| $1.95B | -489.02% |
NL
|
|
| - | - |
CH
|
